These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37335203)

  • 41. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
    Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
    Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
    Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
    World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA
    J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
    Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
    Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.
    Akyol Ardic U; Ercan ES; Kutlu A; Yuce D; Ipci M; Inci SB
    Child Psychiatry Hum Dev; 2017 Oct; 48(5):699-704. PubMed ID: 27812841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder.
    Beaulieu AM; Tabasky E; Osser DN
    Psychiatry Res; 2019 Nov; 281():112583. PubMed ID: 31600606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder.
    Andrade C
    J Clin Psychiatry; 2015 Jan; 76(1):e72-5. PubMed ID: 25650682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Depress Anxiety; 2006; 23(1):1-5. PubMed ID: 16178009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
    Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review.
    Amerio A; Odone A; Ghaemi SN
    J Affect Disord; 2019 Apr; 249():15-19. PubMed ID: 30743017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
    Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
    BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.